BLMS Stock Overview
Manufactures, markets, and distributes cannabidiol products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bloomios, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.005 |
| 52 Week Low | US$0.0001 |
| Beta | 1.09 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -97.22% |
| 33 Year Change | -99.99% |
| 5 Year Change | -99.95% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BLMS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | -97.2% | 10.0% | 31.7% |
Return vs Industry: BLMS underperformed the US Pharmaceuticals industry which returned 24.4% over the past year.
Return vs Market: BLMS underperformed the US Market which returned 39.5% over the past year.
Price Volatility
| BLMS volatility | |
|---|---|
| BLMS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BLMS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Mike Hill | www.bloomios.com |
Bloomios, Inc. manufactures, markets, and distributes cannabidiol products. The company’s product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. It sells its hemp derived supplements and cosmetic products through wholesale and retail distribution channels.
Bloomios, Inc. Fundamentals Summary
| BLMS fundamental statistics | |
|---|---|
| Market cap | US$6.79k |
| Earnings (TTM) | -US$39.61m |
| Revenue (TTM) | US$8.23m |
0.0x
P/S Ratio0.0x
P/E RatioIs BLMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLMS income statement (TTM) | |
|---|---|
| Revenue | US$8.23m |
| Cost of Revenue | US$6.18m |
| Gross Profit | US$2.05m |
| Other Expenses | US$41.66m |
| Earnings | -US$39.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 24.96% |
| Net Profit Margin | -481.28% |
| Debt/Equity Ratio | -76.6% |
How did BLMS perform over the long term?
See historical performance and comparison